AstriVax
Ambachtenlaan 1
Heverlee 3001
BE
AstriVax
Foundation date
30/06/2022
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on vaccine technology developed at the Rega Institute. AstriVax is building a first-in-class Plug & Play vaccine platform with a patented DNA-based technology that launches self-amplifying live attenuated viruses. The versatile technology of AstriVax can be used to develop a wide range of vaccines to prevent and treat infectious diseases. AstriVax aims to address major challenges in vaccinology by developing novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens.
Upcoming events
All events-
0411 '24
BIO-Europe® 2024 - 30th Annual International Partnering Conference
Event by: EBD Group -
1012 '24
Next-Generation Synthetic Biology
Event by: VIB -
0312 '24
BioFIT 2024
Event by: Eurasanté
Latest news
More newsJobs
More jobs-
-
-
30/10/24
Flemish Brabant
Professor in Food Microbiology: Applications of microbes in the food chain (ref. ZAP-2024-87)
Permanent
KU Leuven
More info?
Ellen Telleir
Communication Coordinator